 NEW YORK and LONDON, Sept. 22, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced its financial results for the second quarter of 2021, as well as recent clinical progress. 